GOLDFINCH BIOPHARMA
Goldfinch is a clinical-stage biotech company focused on discovering and developing precision therapies for patients with kidney disease. It is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Its Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. The company was founded in 2016 and is based in Cambridge, Massachusetts.
GOLDFINCH BIOPHARMA
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.goldfinchbio.com
Total Employee:
11+
Status:
Active
Contact:
(617)337-4200
Total Funding:
210 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Domain Not Resolving Wordpress Plugins
Similar Organizations
Anchiano Therapeutics
Anchiano is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Noctrix Health
Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness.
Current Advisors List
Board_member
2020-06-01
Current Employees Featured
Anthony G. Johnson President and CEO @ Goldfinch Biopharma
President and CEO
2017-12-01
Kyle Kuvalanka Chief Financial & Operating Officer @ Goldfinch Biopharma
Chief Financial & Operating Officer
2020-04-01
Edwin J. Tucker Chief Medical Officer @ Goldfinch Biopharma
Chief Medical Officer
2022-01-01
Peter Mundel Co-Founder & Executive Scientific Advisor @ Goldfinch Biopharma
Co-Founder & Executive Scientific Advisor
2019-11-01
Mike Donaldson SVP Finance and Corporate Controller @ Goldfinch Biopharma
SVP Finance and Corporate Controller
2021-10-01
Founder
Investors List
BlackRock
BlackRock investment in Series B - Goldfinch Biopharma
Gilead Sciences
Gilead Sciences investment in Series B - Goldfinch Biopharma
Schroder Adveq
Schroder Adveq investment in Series B - Goldfinch Biopharma
Ally Bridge Group
Ally Bridge Group investment in Series B - Goldfinch Biopharma
Irving Investors
Irving Investors investment in Series B - Goldfinch Biopharma
Eventide
Eventide investment in Series B - Goldfinch Biopharma
Regent Capital
Regent Capital investment in Series B - Goldfinch Biopharma
Casdin Capital
Casdin Capital investment in Series B - Goldfinch Biopharma
Wellington Management
Wellington Management investment in Series B - Goldfinch Biopharma
Gilead Sciences
Gilead Sciences investment in Corporate Round - Goldfinch Biopharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-24 | Goldfinch Bio Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer |
Official Site Inspections
http://www.goldfinchbio.com
- Host name: 71.29.184.35.bc.googleusercontent.com
- IP address: 35.184.29.71
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Goldfinch Biopharma"
Goldfinch Biopharma - Crunchbase Company Profile
Organization. Goldfinch Biopharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email info@goldfinchbio.com; Phone Number (617)337-4200; Goldfinch is a …See details»
Goldfinch Bio - Craft
May 8, 2019 Goldfinch Bio (formerly known as Goldfinch Biopharma) is a company that develops precision medicines for patients with kidney disease. It offers KGA platform that …See details»
Goldfinch Bio Company Profile 2024: Valuation, …
Publication ID Patent Title Status First Filing Date Technology (CPC) Citations; EP-4114838-A1: 1,2,4-triazolinone cb1 inhibitors: Inactive: 02-Mar-2020: EP-4037680-A1See details»
Goldfinch Bio has its wings clipped, shutting down after 7 years
Jan 27, 2023 Goldfinch Bio, a 2020 Fierce Biotech Fierce 15 winner, is shutting down. | Goldfinch Bio, a 2020 Fierce Biotech Fierce 15 winner, is closing its doors after seven years. …See details»
Goldfinch Bio Shutting Down - Global Genes
Rare Daily Staff. Goldfinch Bio, which raised $100 million in 2020 to advance development of experimental therapies for rare and metabolic kidney diseases, is shutting down after it was …See details»
Goldfinch Bio - LinkedIn
Goldfinch Bio Biotechnology Research Cambridge, Massachusetts 3,811 followers We aspire to save kidneys and end dialysis by delivering disease-modifying precision medicines for patients.See details»
Goldfinch Biopharma | Golden
Goldfinch Biopharma is a precision medicine kidney company. The company focuses on its mission to deliver disease-modifying precision medicines that bring hope and renewed quality …See details»
Goldfinch Biopharma - Funding, Financials, Valuation & Investors
Goldfinch Biopharma has a post-money valuation in the range of $100M to $500M as of Jul 1, 2020, according to PrivCo.Sign up for a free trial to view exact valuation and search …See details»
Goldfinch Bio CEO and Key Executive Team | Craft.co
Goldfinch Bio's President, Chief Executive Officer, Director is Anthony Johnson. Other executives include Kyle Kuvalanka, Chief Financial and Operating Officer; Lori Rudolph-Owen, Chief …See details»
Goldfinch Bio - VentureRadar
Similar Companies: Amgen USA Publicly Traded Amgen is one of the world’s leading biotechnology companies. Amgen is a pioneer in the science of using living cells to make …See details»
Goldfinch Bio Expands Executive Leadership Team
Apr 30, 2020 For more information about Goldfinch Bio, visit www.goldfinchbio.com. Contacts Goldfinch Bio Contact: Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.comSee details»
Gilead Sciences and Goldfinch Bio Announce Strategic …
May 8, 2019 -- Companies to Pursue a Human Genetics Approach to Drug Discovery and Development --FOSTER CITY, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 8, …See details»
Goldfinch Bio Strengthens Leadership Team with ... - Business Wire
Dec 6, 2021 Visit us at www.goldfinchbio.com to learn more. Contacts. Goldfinch Bio: Investors: Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 …See details»
Goldfinch Bio to Present Initial Data from Phase 1 Clinical Trial of ...
May 31, 2022 Visit us at www.goldfinchbio.com to learn more. Contacts. Goldfinch Bio Contacts: Investors: Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 …See details»
Goldfinch Bio Expands Leadership Team with World-Class …
Sep 26, 2017 For more information, please visit www.goldfinchbio.com. Goldfinch Bio Contact Jennifer Williams Cook Williams Communications, Inc. [email protected] 360-668-3701. …See details»
Kidney Genetics Company Goldfinch Bio Launched with $55M …
Dec 14, 2016 Life science-focused venture capital firm Third Rock Ventures announced today a $55 million Series A financing of Goldfinch Bio, a company focused on the discovery and …See details»
Goldfinch Bio to Participate in Upcoming Industry Conferences
Feb 23, 2022 Visit us at www.goldfinchbio.com to learn more. Contacts. Goldfinch Bio Contacts: Investors: Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 …See details»
Goldfinch Bio Secures $100 Million in Series B Financing
Jun 30, 2020 For more information about Goldfinch Bio, visit www.goldfinchbio.com. 1 Patients diagnosed with treatment resistant minimal change disease, which is considered a subset of …See details»
After its $2B Gilead pact, Goldfinch Bio nabs a cool $100M series B
Jun 30, 2020 Goldfinch is now pushing two programs through development: GFB-887, a first-in-class selective inhibitor of transient receptor potential canonical channel 5 (TRPC5), and GFB …See details»
Goldfinch Bio Announces Publication in - Business Wire
Jul 7, 2022 Visit us at www.goldfinchbio.com to learn more. Contacts. Goldfinch Bio Contacts: Investors: Hannah Deresiewicz Stern Investor Relations, Inc. 212-362-1200 …See details»